Idiopathic CD4 + lymphopenia
Repeated presence of a CD4 + T lymphocyte count of <300 cells/ml without a predisposing cause.
Epidemiology

HIV-associated cryptococcal infection
In a landmark 2009 study, the Centers for Disease Control and Prevention (CDC) estimated the global burden of HIV-associated CM on the basis of available incidence data in HIV-infected cohorts in different regions. According to the CDC, the incidence of CM was estimated at close to one million cases per year, with at least 100,000 and perhaps as many as 500,000 deaths per year in Sub-Saharan Africa alone 10 . Other data, suggesting that in some populations 10-15% of AIDSrelated deaths (which peaked at 2.3 million per year in 2005 according WHO figures) are caused by cryptococcal disease 11 , also put the number of CM-associated deaths in the hundreds of thousands. An updated analysis by Boulware and colleagues, some of whom were from the CDC, has used a different approach, based on the number of patients at risk (those with CD4 + T cell counts <100 cells/μl and not on effective antiretroviral therapy (ART)), the prevalence of cryptococcal antigenaemia and risk of CM progression. This analysis indicates a lower number of CM-related deaths, but nevertheless estimates CM to cause 140,000 deaths per year, of which 102,000 are in Africa, and suggests that CM accounts for 17% of AIDS-related mortality 12 .
In Europe and North America, the numbers of cryptococcal cases fell dramatically after introduction of effective ART, with hospitalizations falling by half according to one US study 5 . In South Africa, where cryptococcal surveillance has been carried out since the early 2000s, incidence has modestly reduced from a peak between 2005 and 2009 (REF. 13 ).
Importantly, however, there is as yet no evidence of a decrease in cases in many high-incidence African countries despite increased access to ART 14 . In Botswana, which has a relatively well-resourced and functioning ART programme, nationwide surveillance shows that the numbers of cryptococcal cases have actually increased since 2011, probably driven by the numbers of patients defaulting from care 15 . Although total numbers of CM cases remain relatively static, the management of CM is complicated by the fact that in many centres, half of all patients with CM now present with a history of ART use, but with persisting low CD4 + T cell counts due to loss to follow-up, non-adherence, and/or the development of ART resistance (Harrison, T. et al. unpublished enrolment data from the ACTA trial, ISRCTN 45035509) 16, 17 .
Infection in HIV-negative individuals
In many low-income and middle-income countries, the incidence of HIV-associated CM dwarfs that of non-HIV CM. Nevertheless, cryptococcal meningitis is a significant problem in transplant recipients and other patients with defects in cell-mediated immunity, with high rates of death despite therapy 5 . In a US series of over 300 HIV-negative patients with cryptococcal infection, half had CNS involvement and of these, 25% had received steroid therapy, 24% had chronic liver, kidney or lung disease, 16% had a malignancy, and 15% had received solid organ transplants 18 . Haematopoietic malignancies are associated with an increased risk of CM, although stem cell transplant patients are typically not at increased risk because of widespread use of azole prophylaxis in this population. In addition, there is a well-recognized but poorly understood association with sarcoidosis, as well as other autoimmune diseases such as ankylosing spondylitis, dermatomyositis, systemic lupus erythematosus, and autoimmune hepatitis, although some of these associations could be attributed to steroid therapy 19 . Interestingly, even in the developed world, mycobacterial disease is an associated comorbidity 5 , possibly because of shared susceptibility to these two intracellular pathogens because this relationship is seen in HIV-related cases as well 20 . Of note, in the US series, 30% of the patients had no apparent underlying condition. C. neoformans cases occur in apparently immunocompetent patients across the world, with large numbers reported in the Far East 4 . In addition, meningitis caused by C. gattii occurs throughout the tropics, including Australasia 21 and South America, in apparently immunocompetent patients, and notably in the outbreak in Pacific Northwest of North America that has been ongoing since 1999 (REF. 6 ).
Immunodeficiency syndromes. CM in previously healthy individuals is relatively rare, with approximately 3,000 cases reported annually in the USA, which would put the incidence at approximately one in 100,000 individuals per year. This incidence rate suggests that these apparently 'normal hosts' , could in fact harbour rare primary immune defects or uncommon autoimmune diseases.
As shown in BOX 2, a number of immune deficiencies have been associated with cryptococcal meningitis.
Idiopathic CD4
+ lymphopenia (ICL) is the best-known risk factor. In a recent meta-analysis of ICL cases, cryptococcosis was the most common infection, seen in 27% of reported cases 22 . ICL is a heterogeneous disease of unknown cause, although several potentially related monogenic mutations have been reported, including a recent association between defects in T-cell receptor signalling and a mutation in the UNC119 gene 23 .
Key points
• In most clinical centres in Africa, despite access to antiretroviral therapies, cases of HIV-associated cryptococcal meningitis (CM) are not decreasing owing to challenges with retention and adherence to HIV care • CM in HIV-negative individuals is relatively rare, but carries a mortality at least as high as in HIV-associated disease; therefore, CM must be considered in all cases of lymphocytic meningitis -even in the apparently immunocompetent • A point-of-care, lateral flow 'dipstick' test to detect cryptococcal antigen in the blood or cerebrospinal fluid (CSF) is a significant advance: it is highly specific, sensitive, and easy to use • Amphotericin B (in conventional or liposomal formulation) combined with flucytosine remains the induction therapy of choice, and is associated with a survival advantage over amphotericin B alone • Measurement of CSF opening pressure and appropriate management of raised CSF pressure can reduce mortality • Any future attempts at adjunctive immunotherapies will need to be closely guided by the specific immune status of the host at the time of any intervention Pulmonary alveolar proteinosis, which is characterized by the presence of autoantibodies against granulocytemacrophage colony stimulating factor (GM-CSF), has been associated with intracellular infections, including cryptococcosis 24 . Some apparently immunocompetent patients with CM, including some with C. gattii infection in the Pacific Northwest, have been reported to have GM-CSF antibodies, which inhibit macrophage signalling by blocking STAT5 phosphorylation 25, 26 . Autoantibodies against IFN-γ have also been associated with cryptococcal disease 27 . Cryptococcosis has also been associated with syndromes caused by monogenic mutations, including an autosomal dominant sporadic monocytopenia caused by mutations in GATA2 zinc finger transcription factor, which is essential for lymphatic angiogenesis [28] [29] [30] , hyperimmunoglobulin E recurrent infection syndrome 31, 32 , as well as X-linked hyper-IgM immunodeficiency, which has been associated with a number of mutations 33, 34 . In addition, although CM in previously healthy patients is a rare disease, common genetic polymorphisms in, for example, FCy receptor IIB have been associated with disease in this population, and could represent disease modifier genes 35 .
Clinical features, pathology, radiology
Cryptococcal meningitis is a subacute meningoencephalitis. The organism is acquired by inhalation, but can then disseminate, probably in many cases after a latent period of being contained within lung lymph nodes 8 . Whilst involvement of almost all organs and tissues has been reported, Cryptococcus spp. have a strong predilection for the CNS. This neurotropism has been linked to a number of cryptococcal-specific virulence factors that facilitate penetration of the blood-brain barrier, such as specific metalloproteinases and ureases; enzymes that cause neuroimmunomodulation, such as a dopamineutilizing laccase; and mechanisms that facilitate survival within the nutrient-deprived environment of the brain, such as autophagy and high-affinity sugar transporters 36 . Thus, patients with CM present with neurological symptoms, most typically headache and altered mental status, as well as with fever, nausea and vomiting. The median duration from symptom onset to presentation is 2 weeks in patients with HIV infection and 6-12 weeks in non-HIV CM cases. Many patients develop visual symptoms, such as diplopia and, later in the disease, reduced acuity secondary to high CSF pressure (see below), and/or involvement of the optic nerve and tracts 37 . Without treatment, the disease progresses and symptoms extend to confusion, seizures, reduced level of consciousness, and eventually coma.
Many patients also have concomitant lung involvement, although in HIV-associated CM, this is often overlooked or misdiagnosed as tuberculosis 38 . Indeed, although meningoencephalitis dominates the clinical presentation in HIV-infected patients, disseminated infection is probably common. In patients without HIV infection, patients exhibit marked heterogeneity, and clinical presentation can be influenced by host immune responses in particular, and fungal species or lineage differences. For example, organ transplant recipients undergoing intensive immune conditioning can have shorter-lasting presentations with limited inflammatory sequelae, or present with immune reconstitution inflammatory syndrome (IRIS)-like characteristics after reductions of immunosuppression 39 . Previously healthy HIV-negative patients infected with either C. neoformans or C. gattii typically have a more chronic course
Box 1 | Ecology, evolution and virulence of Cryptococcus
Cryptococcus is a genus within the Tremellales, an order of fungi that are commonly found growing on rotting wood as saprophytes and are called 'jelly fungi' because of their gelatinous fruiting bodies. Over 30 species of Cryptococcus are known; two of these, C. neoformans and C. gattii, cause the majority of human infections. Both species can be easily extracted from the environment: they can be isolated from the bark of a wide variety of tree species and from other organic matter, notably, bird faeces.
Cryptococci are sapronoses 138 , a class of accidental parasites which primarily infect immunocompromized individuals, and which gain no evolutionary advantage from infecting the human host 139 . The virulence of Cryptococcus, therefore, is most likely owed to adaptations that allow it to survive in the environment 140 . An array of recognized 'dual-use' virulence factors are known 141 , including a thick polysaccharide capsule 142 , which in the environment defends against parasitic amoeba; however in the human, the capsule allows the fungus to survive macrophage assault and to disseminate as an intracellular parasite.
Genetic analysis has shown that C. neoformans and C. gattii have had independent evolutionary histories for an estimated 30-40 million years 143 . This separation has resulted in subtle variation in their virulence, with C. neoformans being the predominating infection in immunocompromized individuals (that is, individuals with HIV infection or AIDS), whereas C. gattii is a rarer infection and is seen in putatively immunocompetent individuals. Both species are highly diverse and have a number of phylogenetically distinct lineages that are likely to represent cryptic species; the two species are currently undergoing taxonomic revision and could be divided into seven species 144 . Genomic analysis of C. gattii has described four main major lineages (var. gattii (VG) I-IV) 145 . Population genetic analyses suggest that the hypervirulent VGII lineage originates from South America 146 . C. neoformans is similarly diverse, with two recognized cryptic species, each containing evolutionary distinct lineages: C. neoformans var. grubii (lineages var. neoformans (VN) I, II, and NB), which appears to have a centre of diversity in Africa, and C. neoformans var. neoformans (lineage VNIV). Both C. gattii and C. neoformans are facultatively sexual with a bipolar mating system, and hybrids can form between species and between lineages. To date, no important differences in susceptibility to antifungal drugs has been found between cryptococcal species and lineages.
Colony forming unit
A measure to quantify viable fungal cells on the basis of the cells' ability to grow to form visible colonies on an agar plate.
Rate of infection clearance
The rate of decrease in viable organisms in the cerebrospinal fluid (CSF) during treatment, derived from quantitative cultures of the CSF obtained from serial lumbar punctures done over the first 14 days of treatment. For a particular drug regimen, the early fungicidal activity is the mean rate of infection clearance for patients on that regimen.
of CM that often does not feature fever, which can delay diagnosis. Inflammatory sequelae, including hydrocephalus, can be present at diagnosis or occur during therapy, and are reported more frequently with C. gattii than with C. neoformans 40 , perhaps because C. gattii infection induces secretion of higher levels of proinflammatory cytokines than does C. neoformans infection 41 .
In an autopsy series, HIV-associated CM was characterized by the presence of numerous, predominantly extracellular organisms throughout the parenchyma and meninges, sometimes in grossly visible accumulations, with little inflammatory response 42 . In non-HIV individuals, there are fewer organisms, largely confined to the meninges and large perivascular Virchow-Robin spaces, and the infection is associated with a diverse inflammatory response ranging from granulomatous to a more disorganized macrophage infiltration 42, 43 . Immunohistochemistry studies also demonstrate cryptococcal capsule polysaccharide throughout the brain, localized in macrophages and microglia, especially in HIV-associated cases 44 . Brain MRI can detect many of these pathological features, including dilated Virchow-Robin spaces, pseudocysts, cryptococcomas, and cortical and lacunar infarcts 45, 46 . In HIV-negative cases, a larger proportion of patients have large space-occupying cryptococcomas with a marked surrounding inflammatory response, and hydrocephalus.
Outcomes and prognostic factors
Outcomes for patients with HIV-associated cryptococcal meningitis in Africa remain poor, with overall best estimates suggesting a 3-month mortality of 70%, driven by late presentation, and lack of access to drugs, manometers, and optimal monitoring. In prospective research studies, for patients treated with fluconazole, mortality at 10 weeks is 50-60% [47] [48] [49] . Although amphotericin B-based treatment is associated with better outcomes, in trial settings, mortality at 10 weeks is still 24-42% 16, [50] [51] [52] . Mortality remains high even in resourcerich settings: studies from the USA and France suggest that 10-week mortality is 15-26%, and has not changed since the availability of ART [53] [54] [55] . In a US study, 90-day mortality in HIV-negative patients was 27% -higher than in HIV-positive patients 56 . The high mortality in HIV-negative patients is potentially caused by delays in diagnosis and dysfunctional immune responses 57 . In HIV-negative individuals, C. gattii tends to cause more numerous granulomatous lesions in both the lung and the brain, and these patients have more neurological sequelae 6, 40, 58 . In HIV-infected individuals, the presentation and outcomes of C. gattii and C. neoformans infections are not readily distinguishable 59 . A recent analysis of over 500 patients with HIVrelated cryptococcal meningitis confirmed and extended our understanding of the factors associated with poor outcome 60 . The most important of these factors are altered mental status at presentation, and baseline fungal burden (assessed by colony forming unit count). Older age and low weight also confer a poor prognosis 60 . In addition, the rate of infection clearance, which depends on the effectiveness of antifungal therapy and host immune response, is independently associated with outcome 60, 61 , making infection clearance a clinically relevant endpoint for phase II studies of novel antifungal regimens (see below).
In HIV-negative individuals, altered mental status and fungal burden are important prognostic factors. In addition, markers of a poor inflammatory response, low CSF white cell count, and absence of headache, as well as underlying haematological malignancy or chronic renal and liver disease, have been linked with poor prognosis 18, 58, 62, 63 .
Immune responses in HIV-infected patients Jarvis et al. have carried out detailed analyses of local and systemic immune responses in patients with HIVassociated cryptococcal meningitis, at baseline and over time on treatment. These analyses have involved cytokine and chemokine profiling of CSF, and determination of the pattern of intracellular cytokine production by CD4 + memory cells when peripheral blood mononuclear cells (PBMC) are stimulated ex vivo with cryptococcal mannoproteins 64, 65 . This linkage of immune response data to clinical parameters and outcomes allows an investigation of responses associated with survival.
In the analyses conducted by Jarvis and colleagues, variation in CSF parameters at baseline could be largely explained by two principal components (PCs): PC1 was driven by increased levels of IL-6 and IFN-γ, and also IL-8, IL-10, IL-17, CCL5 (also known as RANTES) and tumour necrosis factor (TNF), and PC2 by levels of monocyte chemotactic protein 1 (MCP-1), inflammatory protein 1α (MIP-1α) and GM-CSF (discussed below). Consistent with prior work 66 , the proinflammatory response represented by PC1 correlated with high peripheral CD4 + T cell and CSF white cell counts, markers of CSF macrophage activation, reduced fungal • Pulmonary alveolar proteinosis with autoantibodies to GM-CSF [24] [25] [26] • Autoantibodies to IFN-γ 27
Monogenic disorders
• Primary immunodeficiency owing to GATA2 mutations [28] [29] [30] • Chronic granulomatous disease • Hyperimmunoglobulin E recurrent infection syndrome (also known as Job syndrome) 31, 32 • X-Linked CD40L deficiency (also known as hyper-IgM syndrome) 33, 34 Polygenetic modifiers • FCg receptor II polymorphism 
ASSURED criteria
Originally developed by the WHO Sexually Transmitted Diseases Diagnostics Initiative as a benchmark to determine whether new diagnostic tests addressed the needs of their disease control programmes in resource-limited settings: the ASSURED criteria include the test being affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free, and deliverable to end-users.
burden, more rapid clearance of infection, and survival 65 (FIG. 1a) . Analysis of systemic responses showed a similar pattern: patients who survived had a higher proportion of CD4 + memory cells producing IFN-γ and TNF, and polyfunctional cells producing both of these cytokines, than patients who died, whose cryptococcal-specific CD4 + memory cells were dominated by cells producing only MIP-1α 64 (FIG. 2) . Τhe results are consistent with recent independent work that related poor survival to decreased monocyte production of TNF and to reduced IFN-γ responses in whole blood when stimulated with LPS 67 .
Diagnosis
Characteristic CSF parameters in CM include elevated white cell count, with lymphocyte predominance, elevated CSF protein, and low CSF glucose. In HIVassociated cryptococcal meningitis, the CSF white cell count is lower (median 15 × 10 6 cells/l (REF. 60)) and can often be normal. Diagnosis should not be an issue in HIV-associated cryptococcal meningitis, given the high fungal burden. Simple India Ink examination of the CSF has a 70-90% sensitivity, and cases tha t are negative on the India Ink test can be reliably diagnosed by detection of cryptococcal antigen (glucuronoxylomannan, the dominant capsular polysaccharide) and culture. However, until recently, antigen detection was based on latex agglutination tests, which, although sensitive and specific, were never widely available in high-burden, resource-limited settings.
In the context of limited resources, development of a lateral flow assay (LFA; manufactured by IMMY) has been a major advance. The test meets the ASSURED criteria 68 for point-of-care tests, has a 2-year shelf life at room temperature and requires no specimen preparation. In addition, it is in the order of 100-fold more sensitive to polysaccharide across the four cryptococcal serotypes than the older latex agglutination tests, 69, 70 . Availability of this test makes the screen and pre-emptive therapy prevention strategy feasible (discussed below). It also enables earlier diagnosis (that is, diagnosis before lumbar puncture) through testing of serum, plasma, or whole-blood finger prick samples 71 in primary care settings, and through screening of medical inpatients in high-incidence areas. Of note, although urine samples contain antigen, they are prone to producing false positive results with the current LFA test 72, 73 . More studies are needed to demonstrate whether earlier, LFA-based diagnosis translates to improved outcomes.
A second, semi-quantitative, lateral flow test is now in development by Biosynex and Institut Pasteur in Paris, France. The positive test result consists of either one (low antigen level) or two (high antigen level) bands; this gross approximation of fungal burden might prove useful in individualizing treatment, especially in the setting of screening.
Fungal burden can be low in some cases of HIVassociated unmasking CM that present after initiation of ART, as immune reconstitution can have a more dominant role than active infection (see below) in this context. In these patients, CSF cultures can be negative.
Similarly, in non-HIV CM, cultures and latex agglutination tests, especially for C. gattii, can be negative, and repeat large-volume CSF samples have sometimes been required in the past 74 . The improved sensitivity of the new LFA test for both Cryptococcus spp. is a major advantage 75, 76 , and means the diagnosis of CM should not be delayed, as long as the diagnosis is considered in all patients with a lymphocytic meningitis, even those who are apparently immunocompetent and/or afebrile.
Antifungal therapy
Current recommendations for first-line antifungal treatment have not changed notably for a decade [77] [78] [79] (TABLE 1) , and are based on a three-step 'induction, consolidation, and maintenance' approach that was first used in the landmark 1997 Mycoses Study Group trial 80 , and has been used in subsequent studies which showed that amphotericin B plus flucytosine led to the most rapid clearance of infection 81 , and demonstrated a survival benefit with this combination over amphotericin alone 82 .
In fact, the latter study found a reduction of almost 40% in the relative risk of death at 10 weeks with addition of flucytosine. Of note, the currently used dosage of flucytosine for 2 weeks in HIV-associated CM, with monitoring of full blood counts rather than drug serum levels, has been found to be well-tolerated [82] [83] [84] ; in pharmacokinetic studies in patients, serum concentrations of flucytosine that are usually associated with bone marrow suppression were not found 85 . Care must be taken, however, to adjust the dose of flucytosine if renal impairment secondary to amphotericin develops.
Importantly, amphotericin B deoxycholate (D-AmB) is associated with renal impairment, hypokalaemia and hypomagnesaemia, and anaemia, especially during the second week of induction therapy 84 . Saline and fluid loading equivalent to giving 1 l of regular saline per day in addition to usual fluid requirements, has been shown to reduce renal impairment 86, 87 , and potassium and magnesium supplements under careful monitoring are recom mended 77 . In a recent analysis, the average fall in haemoglobin during 14 days of treatment with D-AmB was 2.3 g/dl (REF. 84 ), which can pose a challenge in treatment centres where transfusion capacity is limited.
Liposomal amphotericin B (L-AmB) is equally as effective as D-AmB, and is better tolerated 88 . Optimal dosing and schedules for L-AmB are still not defined, and one or few large intermittent doses together with oral therapy could provide a safe and effective induction regimen, which would be more cost-effective and sustainable in resource-limited settings compared with current daily dosing. This approach is being tested in the ongoing Ambition-CM trial 89 . The rate of clearance of infection derived from quantitative cultures of CSF from serial lumbar punctures over the first 2 weeks of treatment provides a statistically powerful and clinically relevant endpoint to explore the activity of new dosages and drug combinations. Such early fungicidal activity (EFA) studies have influenced recommendations where resources are limited. Higher doses of fluconazole, up to 1,200 mg daily, are safe and more fungicidal than previously used lower doses 49 , and the combination of high-dose fluconazole plus flucytosine has an EFA that approaches that measured for amphotericin B alone 90 . This oral combination could also prevent emergence of secondary fluconazole resistance. In addition, shorter, 7-day induction with D-AmB does not seem to lead to reduced EFA, perhaps because D-AmB has a prolonged half-life in brain tissues, and is much better tolerated [91] [92] [93] . On the basis of these phase II studies, high-dose fluconazole combined with flucytosine, and 1-week D-AmB-based induction are both being compared with the standard 2-week course of flucytosine plus D-AmB treatment regimen in African treatment centres in the phase III ACTA trial, which will report in 2017 94 . If these two regimens are as effective as 2 weeks of treatment with D-AmB, both would be much more readily and safely sustained in resource-limited settings.
EFA has also been used to explore the in vivo efficacy of established drugs that are known from preclinical studies to have anticryptococcal activity, for possible repurposing for CM. Addition of sertraline to amphotericin B plus fluconazole was associated with an increase in EFA in a Ugandan cohort, compared with historical controls treated without sertraline at the same centre 17 , and is being tested now in phase III (results expected in 2018 95 ). A number of other candidate agents are suitable for similar testing 96 . At least one new agent, Viamet 1129, is being developed specifically for CM. It is a novel oral azole-like compound that concentrates in brain tissue and shows impressive fungicidal activity in animal models. Phase I studies of Viamet 1129 have started, with phase II EFA studies under development.
In patients without HIV, the clinical response depends on control of aberrant immune responses as much as it depends on control of the initial infection. Initial therapy with amphotericin B and flucytosine is similar to that for HIV-related disease, but the induction phase is longer (4-6 weeks 6,78,97 ) (TABLE 1) and lipid formulations have been favoured over the deoxycholate preparation because of reduced renal toxicity. Previously healthy patients with idiopathic CD4 + lymphopenia can take longer to respond microbiologically but have less immune sequelae, whereas those with normal CD4 + T cell counts can have immune sequelae on presentation or, in an important minority, such sequelae can develop despite microbiological control (discussed below).
Reduction of immunosuppression in solid organ transplant recipients is an intuitively logical approach after severe infections such as cryptococcosis, and is well tolerated. However, discontinuation of calcineurin agents and similar drugs has been associated with clinical deterioration and IRIS, although discontinuation of corticosteroids was not 98, 39 . Calcineurin inhibitors have an added benefit of being synergistic with antifungals against Cryptococcus, and have been associated with better outcomes in post-transplant cryptococcosis 99 .
Raised CSF pressure Half of HIV-infected patients with CM have a CSF opening pressure of >25 cmH 2 O, with roughly a quarter of patients having a very high pressure of >35 cmH 2 O (REFS 60,100). High pressure is associated with worse symptoms, including headache, nausea, diplopia secondary to sixth nerve palsies, and altered mental status.
Head scans show that hydrocephalus is rare in HIVassociated meningitis 45 , and the pathophysiology is most likely attributed to blockage of CSF reabsorption by alive or dead organisms, and/or shed cryptococcal polysaccharide at the level of the arachnoid granulations and other sites of CSF reabsorption 101 . In a small postmortem patient series, arachnoid granulation tissue contained many fungal cells in comparison with the rest of the brain, and high numbers of organisms were associated with increased premorbid CSF pressure 101 . Interestingly, a high fungal burden appears necessary but not sufficient for the development of high pressure, suggesting that other pathogen or host factors must be involved 102 .
Based on this understanding of mechanism, careful therapeutic lumbar punctures are recommended to control high CSF pressure. The safe maximum volume of CSF that can be drained at one lumbar puncture is unclear, but up to 30 ml are frequently removed in patients with high pressure, with checking of pressure after each 10 ml removed. Increasing evidence points convincingly to the efficacy of this procedure. In the original data from the 1997 Mycoses Study Group trial, high pressure was associated with increased acute mortality 100 , whereas in a large cohort of patients in whom regular lumbar punctures were performed with additional therapeutic lumbar punctures if the pressure was high, there was no association of high baseline pressure with mortality. In fact, the opposite trend was seen 60 . In addition, adherence to guidelines regarding CSF pressure measurement and management has been associated with improved outcome 103 , and, in a Ugandan study, therapeutic lumbar punctures were associated with reduced mortality, irrespective of baseline pressure 104 . Importantly from a clinical standpoint, it is well recognized that high CSF pressure, even if absent on presentation, can develop later, despite sterilization of CSF, typically in the second and third weeks of antifungal therapy 102 . Thus, it is vital that lumbar puncture is repeated and pressure is measured in patients who do not improve or in whom symptoms recur.
Repeated daily therapeutic lumbar punctures are sufficient to control raised pressure in the majority of patients. Occasionally, however, only a temporary lumbar drain, ideally managed on a neurosurgical facility, which allows an order of magnitude more CSF to be safely drained per day, is sufficient 105, 106 . Our own and others' experience suggests that around 7 days of temporary drainage is usually required 106 (FIG. 3) . Ventricular shunts are also effective, but can usually be avoided in HIV-associated CM.
By contrast, an important minority of HIV-negative individuals with CM have central obstruction of the choroid plexes within the foramina of the fourth ventricle that is accompanied by hydrocephalus, or a superior arachoiditis and a communicating process of elevated pressures, both of which are associated with robust inflammatory responses 43 . Thus, in meningitis that is not associated with HIV, shunts are needed more often because of hydrocephalus or persistent obstruction, and can be used safely provided antifungal therapy has been started 107 .
Cryptococcal IRIS CM-associated IRIS is another common and lifethreatening complication. In the context of HIV, there are two forms of IRIS: paradoxical IRIS in patients who respond to antifungal therapy for CM before starting ART and then have a relapse of CM symptoms after starting ART; and unmasking IRIS in individuals who present with CM for the first time after ART is started 108 .
Paradoxical IRIS
Paradoxical CM-IRIS remains a diagnosis of exclusion, and the reported rates of paradoxical IRIS vary depending on how thoroughly alternative diagnoses can be investigated. Parodoxical IRIS probably occurs in 10-20% of patients who survive CM long enough to start ART, and the condition is most likely to develop at a median of 1-2 months after ART initiation [109] [110] [111] . Risk factors for CM-IRIS include a low pre-ART CD4 + cell count that rises rapidly after ART initiation, a low initial CSF white cell count, low markers of inflammation and IFN-γ responses on initial presentation, and a high fungal burden at baseline and day 14 .
In the principal component analysis of baseline CSF cytokine profiles by Jarvis et al. (described earlier), the second principal component -which was driven by high concentrations of chemokines, MCP-1 and MIP-1α, and GM-CSF -was associated with the subsequent development of IRIS 65 (FIG. 1b) ; consistent with prior findings by Chang et al. 115 . These chemokines might enhance T and myeloid cell trafficking into the CNS, resulting -once restoration of CD4 + T H 1 subsets occurs following initiation of ART -in the excessive T H 1-type immune responses seen during CM-IRIS episodes 57, 110, 116, 117 (FIG. 4) .
As with other opportunistic infections, the question arises as to how to best time ART to avoid precipitating IRIS, while establishing HIV therapy as soon as possible. For cryptococcal disease, we know that ART initiation at 3-8 days after presentation 118, 119 is too soon, and at 6 weeks is probably unnecessarily late 120 . In the Cryptococcal Optimal ART Timing (COAT) study 119 , as early as day 14 after presentation, patients given early ART (median initiation at 8 days) were found to have higher CSF white cell counts and CSF markers of macrophage and/or microglial activation than patients not yet started on ART, suggesting the excess deaths in the early ART arm may have been immune mediated 121 . Thus, current guidelines suggest that ART is initiated at 4-6 weeks, although cohort evidence suggests that starting treatment during the fourth week is safe in the context of rapidly fungicidal induction therapy 60 , which should itself help prevent IRIS. Patients who re-present (that is, get worse and seek care) at the clinic after the start of ART should have an lumbar puncture to screen for ongoing active infection, and re-induction antifungal therapy (TABLE 1) should be considered while awaiting culture results. Moreover, lumbar puncture enables measurement and management of CSF pressure, which is essential given that high pressure is an important feature of paradoxical CM-IRIS. Alternative diagnoses should be actively pursued. While CM-IRIS is clearly life-threatening, it is possible to minimize CM-IRIS mortality with awareness and early recognition, and short courses of corticosteroids for patients who are deteriorating 112 . In some cases, steroid weaning leads to recurrent IRIS, and case reports have described the use of thalidomide and adalimumab in refractory CM-IRIS in both HIV and transplant patients 122, 123 .
Unmasking IRIS
Unmasking HIV-associated CM-IRIS cases are characterized by lower fungal burden compared with ART-naive cases, and some evidence, although not conclusive, points to increased inflammatory responses in unmasking CM-IRIS 124 . The balance between active infection and immune pathology can vary, depending on the interval between ART initiation and presentation. If this interval is just a few days, little difference is seen when compared with ART-naive patients, whereas patients presenting much later may be culture-negative, and are diagnosed on the basis of antigen testing only. Patients presenting with unmasking CM-IRIS are treated with the same antifungal regimens used for those who are ART-naive, although care is needed in view of interactions and overlapping adverse effects between antifungals and ART. Careful assessment is also needed to try to distinguish between unmasking cases, and the increasing number of patients who are ART-exposed but present with CM with persisting low CD4 + cell counts attributed to ART non-adherence and/or resistance. In these latter cases, any switches or re-initiation of ART are best postponed until 4 weeks into antifungal therapy. 
Macrophage-T-cell dissociation
Despite appropriate T-cell signalling, macrophages fail to become classically activated and clear infection but rather remain in an alternatively activated state that is less effective at controlling infection and clearing antigen.
Immune responses in non-HIV patients In the HIV-negative host, paradoxical immune reactions are an important cause of poor outcome in CM. In patients who have previously been immunosuppressed prior to bone marrow transplantation or given chemotherapy for haematological malignancies, reductions in immunosuppressive medications to boost the immune response frequently result in an IRIS-like reconstitution syndrome 39 . In previously healthy individuals in whom no immune reconstitution occurs, clinical deterioration commonly occurs during therapy, not from microbiological failure but from an aggravated immune response, known as post-infectious inflammatory res ponse syndrome (PIIRS).
Primary differences in the non-HIV setting com pared with the HIV setting include compartmental ization, with only intrathecal responses measurable, and in many non-HIV cases an alternatively activated M2-like skewing of CNS-tissue infiltrating macrophages, which has been found to indicate a nonprotective response in animal models of CM 125 . As shown in FIG. 4 , PIIRS shares features with CM-IRIS, including activation of the dendritic cell-T-cell synapse and T-cell inflammatory responses evidenced by elevated cytokines IFN-γ and IL-6. Biomarkers of this inflammatory process are the CSF soluble T-cell activation marker sCD27, which is associated with release of the axonal damage protein, neurofilament light chain. However, the syndrome differs from CM-IRIS in that PIIRS lacks effective activation of macrophages, leading to macrophage-T-cell dissociation; as a result, these patients have persistent tissue antigen and inflammation, and can show clinical deterioration. As shown in FIG. 5 , corticosteroids have been useful in these patients with inflammatory brain lesions, whether infected with C. neoformans or C. gattii, once microbiological clearance is documented by negative CSF cultures 43, 126 .
Prospects for immunotherapies
As exemplified above, an increased understanding of the immunopathology in some non-HIV cases of CM, of immunological predispositions to CM in the heterogeneous group of HIV-negative patients with CM, and of protective immune responses in patients with HIV-associated CM should guide attempts to manipulate immune responses for patient benefit. Any such attempts will need to be tailored to the patient and their immune status at the time, moving the damage-response framework 127 to an optimal balance of effective fungal clearance without immune pathology.
Given that PIIRS in non-HIV CM can be persistent owing to macrophage clearance defects, and the adverse effects of prolonged corticosteroid use, active research is currently directed at identifying steroid-sparing immuno suppressants that are effective in neuroinflammation. In HIV-negative, previously healthy patients, identification of genetic or immunological defects could be useful to guide attempts to augment microbiological control and to identify family members at risk. In addition, diseases such as pulmonary alveolar proteinosis are important comorbidities to identify in non-HIV CM, because pulmonary pathology may be problematic after resolution of meningitis, and a number of therapies, such as aero solized GM-CSF, have proven effective for pulmonary pathology 128, 129 . In HIV-associated CM, clinical trial data are consistent with the immune data from patients, showing the importance of T H 1-type immunity in controlling infection. In a large randomized trial, adjunctive steroids at the time of CM diagnosis were associated with an increased risk of disability or death, increased adverse events, and a substantially reduced rate of fungal clearance 16 . By contrast, in two smaller trials, adjunctive IFN-γ appeared to be safe and augmented clearance without any indication of adverse effects on HIV viral control or IRIS 52, 130 . Perhaps unsurprisingly, the greatest effect was seen in patients with poor baseline T H 1-type responses. Further studies on the risks and benefits of IFN-γ in HIV-associated CM are needed, and rapid assessment of immune status could enable targeting of IFN-γ to patients who are likely to benefit most. Even in HIV-associated CM, the patients' immune responses vary; augmentation of immune responses by IFN-γ should be avoided in patients with late unmasking IRIS, and in those with paradoxical CM-IRIS.
Screening and prevention
Cryptococcal infection can be diagnosed early through detection of cryptococcal polysaccharide antigen in the blood, so screening of patients at very high risk of cryptococcal infection, such as those with late-stage HIV, could provide an opportunity for preventing the development of CM. In one study, the antigen was detectable in the blood at a median of 22 days before development of CNS symptoms 11 . In a retrospective cohort study of over 700 prospectively monitored patients in Cape Town, South Africa, blood samples were taken before initiation of ART 131 . None of the 661 patients who were cryptococcal antigen negative (93%) went on to develop CM in the first year of ART. By contrast, at least 7 of 25 patients (28%) who were antigenpositive with no prior history of CM developed CM during this time. This 100% negative predictive value of antigen-negativity supports the utility of antigen detection in a screen and pre-emptive therapy strategy, whereby patients at risk (with CD4 + T cell counts <100 cells/μl) are tested for antigen and those who tested positive are given pre-emptive therapy with the widely available and safe oral fluconazole. Several modelling studies have suggested that such a strategy would be highly cost-effective, saving lives and money even at very low prevalences of antigenaemia, in light of the fact that the costs of admission and care of prevented cases would be avoided 132, 133 . On this basis, screening was endorsed in WHO guidelines 77 , and programmes initiated in South Africa 134 and elsewhere, and by Médecins Sans Frontières. Some prospective data is now available that supports the screening-based prevention strategy: in a randomized controlled trial in Tanzania and Zambia (REMSTART), screening of patients presenting for ART with a CD4 + T cell count <200 cells/μl, as described above, combined with simple lay-worker ART adherence support for the first month, reduced overall mortality in the first year of ART by 28% 135 . Nevertheless, questions remain regarding how best to implement screening and, in particular, over the best therapy for antigen-positive patients. Data from REMSTART, as well as studies in Uganda and Cape Town, all suggest that the mortality of antigen-positive patients remains much higher, at 25-30%, than antigen-negative patients, which is about 10-12% 73, 135 . Moreover, when the researchers analysed data from patients who had consented to lumbar puncture, as many as ~40%, of serum antigen-positive patients, even if asymptomatic, were found to have CSF antigenaemia, which suggests meningitis 73 . Furthermore, high blood antigen titres can predict those with meningitis 73 , and are associated with a poor outcome 136 . Although fluconazole may be sufficient therapy for many antigen-positive patients, patients with evidence of meningitis may need more-aggressive antifungal therapy. A planned follow-up trial for REMSTART will compare fluconazole with fluconazole plus flucytosine for antigen-positive patients. New semi-quantitative antigen tests could rapidly identify those who would benefit from more-intensive treatment.
Conclusions
Cryptococcal meningitis is a leading fungal cause of human disease and death worldwide. However, expanding access to current antifungal drugs 137 and optimizing their use in regimens that are sustainable in resourcelimited settings, together with earlier diagnosis enabled by a new point-of-care immunodiagnostic test and therapeutic lumbar punctures to manage the common complication of raised CSF pressure, have the potential to markedly reduce the global disease burden. Drug discovery aimed specifically at Cryptococcus spp. is limited, but one promising new agent, Viamet-1129, is now entering clinical evaluation. Immunomodulatory adjunctive therapies, based on advances in our understanding of host immunity in different patient populations, hold promise, but need to be carefully tailored to the individual patient and their immune status at the time. 
